StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) stock

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.17+0.02 (+0.39%)

Close on Nov 18, 2026Market cap $280.03MP/E –Yield –

Eikon Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$88.41M–
Q1 FY2026Mar 31, 2026-$82.96M–
Q2 FY2025Jun 30, 2025-$105.21M–
Q1 FY2025Mar 31, 2025-$68.24M–

More Eikon Therapeutics figures

See a number that looks wrong?